Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier

Rhea-AI Summary

Nascent Biotech, Inc. (NBIO) has been issued a 'Method-of-Use' patent from the Japanese Patent Office for its primary asset, Pritumumab (PTB), related to PTB's capacity to cross through the Blood-Brain Barrier. The patent approval recognizes PTB's ability to act as a monotherapy and as a conjugate, bringing other therapies across the BBB. Nascent's senior management sees this as a significant event elevating the Company's value proposition and strengthening its intellectual property position internationally.

Positive

• Nascent Biotech, Inc. has received a patent approval for Pritumumab's capacity to cross through the Blood-Brain Barrier, strengthening the Company's intellectual property position internationally.

Negative

• None.

NORTH PALM BEACH, FL / ACCESSWIRE / November 29, 2023 / Nascent Biotech, Inc. (OTC:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the Company has been issued a "Method-of-Use" patent from the Japanese Patent Office ("JPO") for its primary asset, Pritumumab ("PTB"). Specifically, the patent approval is related to PTB's capacity to cross through the Blood-Brain Barrier ("BBB").

The patent allowance recognizes PTB's ability to act as a monotherapy, as well as its potential to act as a conjugate, bringing other therapies across the BBB.

In basic terms, the blood-brain barrier is a semipermeable border of endothelial cells that act as a filtering mechanism for the capillaries that carry blood to the brain and spinal cord tissue, blocking the passage of certain substances from the circulatory system into the brain.

Nascent's senior management recognizes this patent approval as a significant event elevating the Company's value proposition. The approval strengthens the Company's intellectual property position, both in general and by providing protection that extends internationally.

"This patent further validates the value of PTB as a unique biotechnology asset," remarked Nascent CEO, Sean Carrick. "It also extends our IP footprint internationally, opening up new market potential, expanding the upside value proposition of PTB commercially. We look forward to providing further highlights and updates related to this as well as our progress in Phase 2 clinical research."

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact
Sean Carrick | CEO | Nascent Biotech, Inc.
sean.carrick@nascentbiotech.com

Public Relations
EDM Media, LLC
https://edm.media
(800) 301-7883

SOURCE: Nascent Biotech Inc.

View source version on accesswire.com:
https://www.accesswire.com/810821/nascent-biotech-granted-japanese-patent-for-crossing-blood-brain-barrier

What patent has Nascent Biotech, Inc. (NBIO) been issued from the Japanese Patent Office?

Nascent Biotech, Inc. has been issued a 'Method-of-Use' patent for its primary asset, Pritumumab (PTB), related to PTB's capacity to cross through the Blood-Brain Barrier.

What does the patent approval recognize about PTB's ability?

The patent approval recognizes PTB's ability to act as a monotherapy and as a conjugate, bringing other therapies across the Blood-Brain Barrier.

How does Nascent Biotech, Inc. view the patent approval?

Nascent's senior management sees this as a significant event elevating the Company's value proposition and strengthening its intellectual property position internationally.